NCT05006911

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

Pilocarpine, Brimonidine, Oxymetazoline Ophthalmic Compound Safety and Efficacy in Patients With Presbyopia

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (estimated)
• Sponsor: Optall Vision · Academic / Other
• Sex: All
• Age: 40 Years – 60 Years
• Healthy volunteers: Accepted

Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Detailed description

To determine the safety and efficacy of a novel pharmacological compound of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) to improve uncorrected near vision in healthy presbyopic patients one hour after binocular instillation.

Conditions

• Presbyopia

Interventions

Type	Name	Description
DRUG	Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound	To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.

Timeline

• Start date: 2021-08-14
• Primary completion: 2021-09-01
• Completion: 2021-09-15
• First posted: 2021-08-16
• Last updated: 2021-08-17

Locations

1 site across 1 country: Mexico